Stifel Financial
RXII

Stifel Financial’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Stifel Financial’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-91,749
Closed -$44K – 2612
2016
Q2 		$44K Buy
+91,749
New +$44K ﹤0.01% 2440

Other funds holding RXII

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Stifel Financial's RXII Position: Q3 2016 in Review

Stifel Financial sold out of GALENA BIOPHARMA INC COM (RXII) in Q3 2016, closing a stake of 91,749 shares — an estimated $44K sold.

Stifel Financial first reported a position in RXII in Q2 2016 and held it in 1 quarter. The position peaked at $44K in Q2 2016. 92 funds tracked by Wall St. Rank hold RXII as of Q3 2016.

  • Stifel Financial reported no remaining GALENA BIOPHARMA INC COM position as of Q3 2016 after selling out during the quarter.
  • Stifel Financial sold 91,749 GALENA BIOPHARMA INC COM shares in Q3 2016, an estimated $44K.
  • Stifel Financial first reported a position in GALENA BIOPHARMA INC COM in Q2 2016 and held it in 1 quarter.
  • Stifel Financial's GALENA BIOPHARMA INC COM position peaked at $44K in Q2 2016.
  • 92 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q3 2016.

Based on Stifel Financial's 13F filing for Q3 2016, filed 15 Nov 2016.